Business
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDTDosing completed in part 1a of phase 2a study of PRS-060/AZD1402Dosing
About this update from Palvella Therapeutics, Inc.
[{"type":"text","content":"Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDTDosing completed in part 1a of phase 2a study of PRS-060/AZD1402Dosing to begin this quarter in phase 2 study of cinrebafusp alfaReceived regulatory approval from multiple countries for phase 1/2 study of PRS-344/ S095012Presented preclinical data for PRS-220 at ERS; on track for 2022 clinical initiationInitiated second costim bispecific program in Seagen collaborationInitiated respiratory and ophthalmology programs with GenentechPromoted Thomas Bures to CFO and Ahmed Mousa to CBOBOSTON, MA / ACCESSWIRE / November 2, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the third quarter of 2021 ended September 30, 2021 and provided an update on the Company's recent and anticipated future developments.\"I am pleased to report that AstraZeneca has completed dosing in part 1a of the phase 2a study of PRS-060/AZD1402. We look forward to announcing the completion of the safety review by AstraZeneca before initiating the second part of that study and presenting topline data informing our co-development opt-in decision next year. Also within our respiratory franchise, we are progressing PRS-220 toward the clinic next year, and we recently presented preclinical data for that program, reinforcing our enthusiasm about it. Additionally, we have made important strides in getting the next phase of clinical trials for our immuno-oncology programs cinrebafusp alfa and PRS-344 activated, and we are excited to see those trials progress,\" said Stephen S. Yoder, President and Chief Executive Officer of Pieris. \"We have a solid balance sheet of over $125 million as we continue to advance a diverse and rich pipeline of fully proprietary and co-developed assets into and through the clinic this year and anticipate several key inflection points in 2022.\"PRS-060/AZD1402 and AstraZeneca Collaboration: Dosing has been completed in part 1a (safety) of the global phase 2a study of PRS-060/AZD1402, an inhaled IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Data unblinding an...